Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NRX PharmaceuticalsNRXP -0.14%31 EV-to-EBITDA is -5.68 as of Sep. 03, 2026. GuruFocus rates NRXP with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 400 Biotechnology companies, NRX Pharmaceuticals ranks worse than 249999.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NRX Pharmaceuticals's enterprise value is $124.15 Mil.
NRX Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-21.86 Mil. Therefore, NRX Pharmaceuticals's EV-to-EBITDA for today is -5.68.
The historical rank and industry rank for NRX Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
NRXP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.19 Med: -2.11 Max: -1.3
Current: -5.68
During the past 6 years, the highest EV-to-EBITDA of NRX Pharmaceuticals was -1.30. The lowest was -6.19. And the median was -2.11.
NRXP's EV-to-EBITDA is ranked worse than 100% of 400
companies
in the Biotechnology industry
Industry Median: 14
vs NRXP: -5.68
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NRX Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
NRX Pharmaceuticals's share price for today is $3.455.
NRX Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for NRX Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NRX Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NRX Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NRX Pharmaceuticals's EV-to-EBITDA falls into.
NRX Pharmaceuticals's current Enterprise Value is $124.15 Mil.
NRX Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NRX Pharmaceuticals (NRXP) has a EV-to-EBITDA of -5.68 as of Sep. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NRX Pharmaceuticals. According to the industry distribution chart, NRX Pharmaceuticals ranks #999999 out of 400 companies in the Biotechnology industry.
Is NRX Pharmaceuticals' EV-to-EBITDA too high?
NRX Pharmaceuticals' current EV-to-EBITDA is -5.68. Based on the distribution chart, NRX Pharmaceuticals ranks #999999 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NRX Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does NRX Pharmaceuticals' EV-to-EBITDA compare to INDP and EQ?
According to the Biotechnology industry distribution chart, NRX Pharmaceuticals ranks #999999 out of 400 companies for EV-to-EBITDA. This places NRX Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 14.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.00, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NRX Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 14.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NRX Pharmaceuticals's current EV-to-EBITDA is -5.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NRX Pharmaceuticals stock overvalued right now?
NRX Pharmaceuticals (NRXP) has a current EV-to-EBITDA of -5.68. The current EV-to-EBITDA is -5.68. NRX Pharmaceuticals' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For NRX Pharmaceuticals (NRXP), the current EV-to-EBITDA is -5.68 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
31GF Score
Get the complete analysis for NRXP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NRXP has been successfully added to your 
